Recommendations for Personalised HCC Treatment With Y90 TheraSphere(TM) Published by an International Multidisciplinary Group
Supported by comparative Dosisphere data, a phase II multicentric randomised dosimetry trial
LONDON, July 23, 2019 -- (Healthcare Sales & Marketing Network) -- BTG plc (LSE: BTG), a global healthcare company, today announced consensus recommendations f... Devices, Interventional, Oncology BTG, TheraSphere, hepatocellular carcinoma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Liver Cancer | Marketing | Pharmaceuticals